Biogen’s Market Paradox: Strong Quarterly Performance Clashes with Cautious Outlook

Biogen finds itself in a curious position, delivering impressive third-quarter 2025 results that simultaneously impressed market analysts and disappointed investors. The biotechnology firm reported earnings of $4.81 per share, substantially exceeding analyst projections by 23.65%, while revenue reached $2.53 billion, also surpassing expectations. Despite these positive indicators, the company’s shares declined nearly 5% in after-hours trading as management revised its full-year guidance downward.

Guidance Revision Overshadows Quarterly Triumph

The market’s negative reaction stemmed primarily from Biogen’s updated financial forecast for 2025. The company now anticipates full-year earnings between $14.50 and $15.00 per share, a reduction of approximately 6% from previous guidance of $15.50 to $16.00 per share. This downward revision has raised fundamental questions about whether the current momentum can be sustained throughout the coming year, despite the quarter’s exceptional performance.

Emerging Therapies Demonstrate Substantial Growth

Biogen’s newer pharmaceutical offerings are showing remarkable market traction. Revenue from recently launched products surged 67% year-over-year, with several treatments posting particularly strong results. The Alzheimer’s therapy Leqembi has emerged as a standout performer, with global sales climbing over 80% to approximately $121 million. In the United States, Leqembi has established itself as the leading anti-amyloid treatment for Alzheimer’s disease.

Additional recently launched medications are contributing significantly to the company’s growth trajectory. Skyclarys generated worldwide sales of around $133 million, while Zurzuvae, targeting postpartum depression, reached $55 million in revenue. These successful product introductions are critically important as Biogen works to offset declining sales from its more established pharmaceutical lines.

Should investors sell immediately? Or is it worth buying Biogen?

Institutional Confidence and Development Pipeline

Despite mixed market signals, institutional investors maintain substantial confidence in Biogen’s long-term prospects. Institutions currently hold 87.93% of outstanding shares, with Wealthfront Advisers notably increasing its position by 129.4% during the second quarter. This institutional support appears well-founded given developments within the company’s research pipeline.

Biogen has resubmitted its application to the FDA for a higher dosage of Spinraza, used in treating spinal muscular atrophy, with an approval decision expected in April 2026. Additionally, accelerated Phase 3 trial results for Litifilimab in treating systemic lupus erythematosus are anticipated during the latter half of next year. Investment firm Guggenheim recently acknowledged these promising developments by raising its price target for Biogen shares from $165 to $185.

The central question facing investors remains whether these emerging blockbuster therapies can sufficiently overcome the dampened earnings forecast and return Biogen to a sustainable growth trajectory.